Eye Chart Pro Remote Control is a companion utility for iPad-based vision testing, allowing clinicians to manage charts via iPhone.
Product velocity
Dormant
Daily rank 🇺🇸
—
Medical
Sentiment
3.0
5 reviews
Nemesis
Fragmented field
The App DNA
What makes this app unique?
Clinicians hire this app to enable wireless control of vision charts, reducing the need for manual interaction with the primary display device during patient exams.
For Eye care professionals and clinicians using iPad-based vision testing software.
What does it look like?
Key features
Turns iPhone or iPod Touch into a wireless controller for iPad-based eye charts.
Connects with Eye Chart Pro, Eye Chart Premium, and Eye Chart Professional iPad apps.
Access to advanced remote control features via the primary iPad app.
How much does it cost?
Freemium model uses the remote app as a free utility to drive adoption of the primary paid iPad medical software.
Velocity
Dormant developmentopaqueShow more...
The app has been inactive for over 18 months, with no releases recorded since November 2024. Given the lack of updates for well over the 3-month threshold, the development status is classified as a zombie. There is no evidence of ongoing maintenance, feature development, or live operations.
Who built it?
Dok
3 apps tracked · Medical
EyeChart - Vision Screening
Eye Chart HDUser Sentiment
What do users think recently?
The recent review mood reads frustrated. Users appreciate the core eye chart functionality provides a usable free tool for basic clinical vision testing.
How are ratings & reviews evolving?
What users say, by theme
- The core eye chart functionality provides a usable free tool for basic clinical vision testing
- Remote control connectivity fails consistently between devices after recent operating system updates
8 of 8 recent reviews analyzed · limited sample · Frustrated overall
Read the full review analysisUnlock 1 more frustration theme and 1 user request, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for Eye Chart Pro Remote Control
How's the Medical market?
The app maintains a 3-star rating across 8 reviews, reflecting significant stability issues. The lack of recent functional updates relative to the competitive landscape signals a loss of market relevance.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Eye Chart Pro Remote Control
Where is it heading?
The clinical vision testing market is shifting toward web-based, hardware-agnostic solutions that offer higher reliability. This app remains exposed due to its reliance on outdated multi-device connectivity, so revenue growth is unlikely without a fundamental shift in technical architecture.
- Persistent connectivity failures between devices after OS updates erode clinical trust, leading to a declining user sentiment trend.
- Users report: Deceptive monetization reports regarding feature access create long-term brand damage, which will likely accelerate churn to more reliable competitors.
The SWOT
- Cross-app integration functions as a suite-retention mechanism for clinical practices
- Visual feedback integration on remote interface to match main display
Next best moves
Rebuild connectivity module because remote control failure is the #1 complaint → restore core clinical utility
+ 1 more prioritized moveThe counter-intuitive read
The app's primary risk is not a lack of features…
Read the full takeFeature gaps
Real-time visual feedback on remote (available in user requests but absent here) +1
Since the last report: The app's competitive position has declined due to critical connectivity failures and user reports of deceptive monetization, shifting the outlook from stable to declining.
Bottom line
The app provides essential clinical utility but suffers from critical connectivity failures, so the PM must prioritize a stability audit to prevent further erosion of the professional user base.
Unlock 2 critical frictions, 1 market threat, 1 more prioritized move and the analyst’s take.
Access the full report for freeReport last updated